Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Will Ibrance receive FDA approval for expanded use in HR+, HER2+ metastatic breast cancer by end of 2025?  | Binary | 3 | 11 days ago | ||
Will Pfizer's Ibrance sales exceed $5 billion annually by end of 2025? | Binary | 3 | 11 days ago | ||
Will Ibrance surpass Kisqali in market share for HR+, HER2+ metastatic breast cancer by end of 2025? | Binary | 2 | 11 days ago | ||
Which company will announce the next breakthrough in HR+, HER2+ metastatic breast cancer by end of 2025? | Categorical | 2 | 11 days ago | ||
What will be the percentage increase in Ibrance's market share for HR+, HER2+ metastatic breast cancer by end of 2025? | Categorical | 2 | 11 days ago | ||
Which region will approve Ibrance for expanded use in HR+, HER2+ metastatic breast cancer by end of 2025? | Categorical | 2 | 11 days ago |